drugset / Trial / NCT02837328

Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias

NCT02837328

Phase 2 Completed 59 enrolled University of Minnesota
RandomizedParallel-groupTriple-blindPrevention

Summary

The primary objective of this research is to determine whether oral magnesium supplementation in healthy, community-living individuals will be associated with reductions in the burden of arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).

Timeline

Start
2017-03-01
Primary completion
2017-09-15
Completion
2017-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium Citrate Unknown 400 mg Oral